Abhoy Sarkar's Avatar
published in Blogs
Jan 03, 2023
RedHill Biopharma (RDHL, $0.17) announces positive data of Phase 2 study of RHB-107 for COVID-19

RedHill Biopharma (RDHL, $0.17) announces positive data of Phase 2 study of RHB-107 for COVID-19

RedHill Biopharma Ltd announced positive observations from a Phase 2 study of RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases.

According to the results, there was a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 treated group versus 15% (3/20) hospitalized on the placebo group. It also revealed an approximate 88% reduction in reported new severe COVID-19 symptoms after treatment was initiated, with just 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled group reporting new severe COVID-19 symptoms.  Further investigation suggested a median of 3 days to recovery from severe COVID-19 symptoms with upamostat – much faster compared to eight days with placebo.

Related Tickers: RDHL